From COVID-19 to influenza A - recurrent viral myocarditis and successful immunosuppressive therapy: A case report and review of literature
World Journal of Cardiology · 26.06.2026 · 18 (6)
DOI: 10.4330/wjc.113066 ↗Kurz gefasst
Fallbericht in der Zeitschrift World Journal of Cardiology, online erschienen am 26.06.2026. Verfasst von Lucia Ilaria Birtolo und 12 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Myocarditis is an inflammatory disease of the myocardium with a highly variable clinical presentation and is often triggered by viral infections. While corticosteroids have historically been used with caution in viral myocarditis due to concerns over impaired viral clearance, recent insights from the coronavirus disease 2019 pandemic suggest that their use may offer clinical benefits in selected cases. Whether such benefits extend to other viral etiologies, including influenza, remains uncertain. We report a case of recurrent viral myocarditis in a young woman, initially following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and later associated with influenza A (H1N1), illustrating diagnostic and therapeutic challenges. CASE SUMMARY A previously healthy 27-year-old woman presented with fulminant myocarditis after a paucisymptomatic SARS-CoV-2 infection. The initial episode was characterized by pericardial effusion, rapidly progressing to cardiogenic shock and severe left ventricular dysfunction, requiring veno-arterial extracorporeal membrane oxygenation. Empirical high-dose corticosteroid therapy, remdesivir, and monoclonal anti-SARS-CoV-2 antibodies led to complete recovery of cardiac function. Two years later, the patient developed recurrent myocarditis triggered by H1N1, presenting with chest pain, elevated cardiac biomarkers, and severe reduction in ejection fraction. Cardiac magnetic resonance confirmed acute myocarditis with severe left ventricular dysfunction. High-dose corticosteroids and levosimendan were administered, resulting in progressive improvement without the need for mechanical support. At discharge, following both episodes, the patient was asymptomatic and had a complete recovery of the left ventricular ejection fraction. Genetic testing was performed to investigate possible predisposition. CONCLUSION This case highlights the diagnostic and therapeutic challenges of recurrent viral myocarditis, as well as the potential role of immunosuppression.
Zitieren
APA
Birtolo, L. I., Ferranti, F., Manzi, G., Caputo, A., Scoccia, G., Bruno, K., Galea, N., Maestrini, V., Chimenti, C., Severino, P., Pugliese, F., Badagliacca, R., & Vizza, C. D. (2026). From COVID-19 to influenza A - recurrent viral myocarditis and successful immunosuppressive therapy: A case report and review of literature. World Journal of Cardiology, 18(6). https://doi.org/10.4330/wjc.113066
Vancouver
Birtolo LI, Ferranti F, Manzi G, Caputo A, Scoccia G, Bruno K, et al. From COVID-19 to influenza A - recurrent viral myocarditis and successful immunosuppressive therapy: A case report and review of literature. World Journal of Cardiology. 2026;18(6). doi:10.4330/wjc.113066
BibTeX
@article{Birtolo2026,
author = {Birtolo, Lucia Ilaria and Ferranti, Federico and Manzi, Giovanna and Caputo, Annalisa and Scoccia, Gianmarco and Bruno, Katia and Galea, Nicola and Maestrini, Viviana and Chimenti, Cristina and Severino, Paolo and Pugliese, Francesco and Badagliacca, Roberto and Vizza, Carmine Dario},
title = {From COVID-19 to influenza A - recurrent viral myocarditis and successful immunosuppressive therapy: A case report and review of literature},
journal = {World Journal of Cardiology},
year = {2026},
volume = {18},
number = {6},
doi = {10.4330/wjc.113066}
}
EUVIMED